CBD maker Elixinol has launched its products across the EU, expanding an existing global network which already embraces Asia, South America, Africa and the United States, where the company is based in Denver, Colorado. The official European launch was May 1, 2017.
Elixinol’s liposomes, tinctures and capsules are in the European portfolio. That includes the company’s newest product, Respira, a line of tinctures that can be vaped, applied topically or taken orally
European customers can access Elixinol through the company’s web site at www.elixinol.com, which has been engineered to identify the customers’ locations and direct them to language-specific pages, the company said. Elixinol’s EU operations are directed by Marco Cappiello, who is based in Holland.
“Normalizing” CBD
Elixinol
As Europe’s CBD market continues on a path toward normalization, it faces the challenge of sorting out what the European Industrial Hemp Association (EIHA) has called a “tenuous patchwork” of rules covering CBD and hemp extracts on the continent. Paul Benhaim, Elixinol’s founder and CEO, said his company brings a philosophy that can help address that challenge and map development of the broader CBD sector in Europe.
“Elixinol’s approach to the multitude of international regulations surrounding CBD is to lead with internal standards higher than the countries require,” Benhaim said. “That includes transparency about our sourcing, our process, ingredients, and independent purity and potency testing.” Normalization of CBD hemp oil globally will require a focus on trust, transparency and safety, Benhaim added. “Anything less than that should be absolutely unacceptable to ourselves and our customers.”
Elixinol’s products are created from organic European industrial hemp plants that undergo a super critical CO2 extraction process to produce whole plant extracts. The products undergo regular testing to ensure the highest potency and purity.
A ‘team investment’
The company’s new all-natural Respira line, which got off to a quick start after being launched earlier this year, comes in grape-mint and natural flavors in dosages of either 300 mg or 600 mg of CBD oil. The multi-purpose CBD product is suitable for consumption orally, topically, or by vape.
“The entire Elixinol team uses our products, so we’re as invested in product quality as our customers are,” said Marco Cappiello. “No one on our team wants to put synthetic, pesticide-filled products in our bodies. We want organic, petroleum-free, safe, effective and tested products too.”
